About Us

A NEW APPROACH TO FIGHT NEURODEGENERATIVE DISEASES

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population.

Led by founder David Elmaleh, Ph.D., a renowned and prolific inventor and molecular scientist, the AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably.

Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease is now fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative diseases.

AZTherapies is a private company headquartered in Boston, Massachusetts.

AZTherapies At A Glance

01

BREAKTHROUGH SCIENCE

Neuroinflammatory mechanism that changes the activation state of microglial brain immune cells from an aggressive, pro-inflammatory state to an anti-inflammatory, neuroprotective state.
02

EXECUTION

Advanced Phase 3 trial of a novel drug combination in early Alzheimer’s Disease. Phase 2a study in patients with mild to moderate ALS. Approved IND for Phase 2 study in post-ischemic stroke. Next-generation compound pre-IND.
03

PATENT PORTFOLIO

More than 100 patents & pending applications claiming novel compositions of matter, formulation, manufacturing and device/delivery for numerous neurodegenerative and other indications.
04

PIPELINE

Multiple follow-on programs with potential to treat and slow the progression of neurodegenerative diseases, while improving the quality of life of the aging population.
05

LEADERSHIP

World class management team, Board of Directors, Scientific Advisory Board, and Business Advisory Board.

Leadership

photo of David Elmaleh

SCIENTIFIC FOUNDER, CHAIRMAN, AND CHIEF EXECUTIVE OFFICER

photo of Karen Reeves, MD

PRESIDENT AND CHIEF MEDICAL OFFICER

photo of Brian Bartlett

CHIEF FINANCIAL & ACCOUNTING OFFICER

large photo of Philip Ashton Rickardt

SENIOR VICE PRESIDENT, IMMUNOLOGY

large photo of David Brazier

VICE PRESIDENT, CLINICAL OPERATIONS

large photo of Ernest Penachio

VICE PRESIDENT, MANUFACTURING OPERATIONS & CMC